Anti-Infective Drugs Advisory Committee; Amendment of Notice, 59570-59571 [E9-27693]
Download as PDF
<![CDATA[
59570
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Notices
mstockstill on DSKH9S0YB1PROD with NOTICES
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Ancillary Studies in Clinical Trials.
Date: December 4, 2009.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Ritz Carlton Hotel, 1150 22nd Street,
NW., Washington, DC 20037.
Contact Person: Chang Sook Kim, PhD,
Scientific Review Officer, Review Branch,
DERA, National Heart, Lung, and Blood
Institute, 6701 Rockledge Drive, Room 7190,
Bethesda, MD 20892, 301–435–0287,
carolko@mail.nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Program Project in Respiratory Muscle
Failure.
Date: December 10, 2009.
Time: 10 a.m. to 2 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: William J Johnson, PhD,
Scientific Review Officer, Review Branch/
DERA, National Heart, Lung, and Blood
Institute, 6701 Rockledge Drive, Room 7178,
Bethesda, MD 20892–7924, 301–435–0725,
johnsonwj@nhlbi.nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
NHLBI Programs of Excellence in
Nanotechology.
Date: December 11, 2009.
Time: 8:30 a.m. to 3 p.m.
Agenda: To review and evaluate contract
proposals.
Place: Ritz Carlton Hotel, 1150 22nd Street,
NW., Washington, DC 20037.
Contact Person: Youngsuk Oh, PhD,
Scientific Review Officer, Review Branch/
DERA, National Heart, Lung, and Blood
Institute, 6701 Rockledge Drive, Room 7182,
Bethesda, MD 20892–7924, 301–435–0277,
yoh@mail.nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Translational Programs in Lung Diseases.
Date: December 17, 2009.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Doubletree Hotel Bethesda
(Formerly Holiday Inn Select), 8120
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Shelley S Sehnert, PhD,
Scientific Review Officer, Review Branch/
DERA, National Heart, Lung, and Blood
Institute, 6701 Rockledge Drive, Room 7206,
Bethesda, MD 20892–7924, 301–435–0303,
ssehnert@nhlbi.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
VerDate Nov<24>2008
16:30 Nov 17, 2009
Jkt 220001
Dated: November 12, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–27703 Filed 11–17–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; ARRA
AREA Special Emphasis Panel 08.
Date: December 4, 2009.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Ritz Carlton Hotel, 1150 22nd Street,
NW., Washington, DC 20037.
Contact Person: Edwin C. Clayton, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5095C,
MSC 7844, Bethesda, MD 20892, (301) 402–
1304, claytone@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA–OD–
09–007: ARRA AREA Grants Panel 05.
Date: December 7, 2009.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Fairmont Washington, DC, 2401
M Street, NW., Washington, DC 20037.
Contact Person: Dana Jeffrey Plude, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3176,
MSC 7848, Bethesda, MD 20892, 301–435–
2309, pluded@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA–OD–
09–007: ARRA AREA Grants Panel 11.
Date: December 7, 2009.
Time: 8:30 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
Contact Person: Jean D. Sipe, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4106,
MSC 7814, Bethesda, MD 20892, 301/435–
1743, sipej@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: November 12, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–27696 Filed 11–17–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–N–0664]
Anti-Infective Drugs Advisory
Committee; Amendment of Notice
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing an
amendment to the notice of meeting of
the Anti-Infective Drugs Advisory
Committee. This meeting was
announced in the Federal Register of
October 26, 2009 (74 FR 55057). The
amendment is being made to reflect a
change in the Location portion of the
document. There are no other changes.
FOR FURTHER INFORMATION CONTACT:
Minh Doan, Center for Drug Evaluation
and Research (HFD–21), Food and Drug
Administration, 5600 Fishers Lane, (for
express delivery, 5630 Fishers Lane, rm.
1093), Rockville, MD 20857, 301–827–
7001, FAX: 301–827–6776, e-mail:
minh.doan@fda.hhs.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington DC area), code 3014512530.
Please call the Information Line for upto-date information on this meeting.
SUPPLEMENTARY INFORMATION: In the
Federal Register of October 26, 2009,
FDA announced that a meeting of the
Anti-Infective Drugs Advisory
Committee would be held on December
9, 2009. On page 55057, in the second
column, the Location portion of the
document is changed to read as follows:
Location: Hilton Washington DC
North/Gaithersburg, The Ballrooms, 620
Perry Pkwy., Gaithersburg, MD. The
hotel telephone number is 301–977–
8900.
E:\FR\FM\18NON1.SGM
18NON1
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Notices
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14,
relating to the advisory committees.
Dated: November 12, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9–27693 Filed 11–17–09; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director, National
Institutes of Health; Notice of Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
Advisory Committee to the Director,
NIH.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
mstockstill on DSKH9S0YB1PROD with NOTICES
Name of Committee: Advisory Committee
to the Director, NIH.
Date: December 4, 2009.
Time: 8:30 a.m. to 5 p.m.
Agenda: Among the topics proposed for
discussion are: (1) NIH Director’s Report; (2)
NIH Director’s Council of Public
Representatives Liaison Report; and (3) other
business of the Committee.
Place: National Institutes of Health,
Building 31, Conference Room 6, 9000
Rockville Pike, Bethesda, MD 20852.
Contact Person: Penny W. Burgoon, PhD,
Senior Assistant to the Deputy Director,
Office of the Director, National Institutes of
Health, 1 Center Drive, Building 1, Room
VerDate Nov<24>2008
16:30 Nov 17, 2009
Jkt 220001
109, Bethesda, MD 20892, 301–451–5870,
burgoonp@od.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page: https://
www.nih.gov/aboutldirector/acd.htm, where
an agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.14, Intramural Research
Training Award; 93.22, Clinical Research
Loan Repayment Program for Individuals
from Disadvantaged Backgrounds; 93.232,
Loan Repayment Program for Research
Generally; 93.39, Academic Research
Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan
Repayment Program; 93.187, Undergraduate
Scholarship Program for Individuals from
Disadvantaged Backgrounds, National
Institutes of Health, HHS)
Dated: November 5, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–27411 Filed 11–17–09; 8:45 am]
BILLING CODE 4140–01–M
PO 00000
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–N–0667]
[FDA 225–09–0013]
Memorandum of Understanding
Between the Food and Drug
Administration and Waterfront Media
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is providing
notice of a memorandum of
understanding (MOU) between FDA and
Waterfront Media. The purpose of the
MOU is to extend the reach of FDA
Consumer Health Information and to
provide consumers with better
information and timely content
concerning public health and safety
topics, including alerts of emerging
safety issues and product recalls.
DATES: The agreement became effective
October 14, 2009.
FOR FURTHER INFORMATION CONTACT:
Jason Brodsky, Consumer Health
Information Staff, Office of External
Relations (HFI–40), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–827–6251, email: Jason.Brodsky@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 20.108(c),
which states that all written agreements
and MOUs between FDA and others
shall be published in the Federal
Register, the agency is publishing notice
of this MOU.
Dated: November 12, 2009.
David Horowitz,
Assistant Commissioner for Policy.
BILLING CODE 4160–01–S
Frm 00052
Fmt 4703
Sfmt 4703
59571
E:\FR\FM\18NON1.SGM
18NON1
]]>Agencies
[Federal Register Volume 74, Number 221 (Wednesday, November 18, 2009)]
[Notices]
[Pages 59570-59571]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-27693]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2009-N-0664]
Anti-Infective Drugs Advisory Committee; Amendment of Notice
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
amendment to the notice of meeting of the Anti-Infective Drugs Advisory
Committee. This meeting was announced in the Federal Register of
October 26, 2009 (74 FR 55057). The amendment is being made to reflect
a change in the Location portion of the document. There are no other
changes.
FOR FURTHER INFORMATION CONTACT: Minh Doan, Center for Drug Evaluation
and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane,
(for express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD
20857, 301-827-7001, FAX: 301-827-6776, e-mail: minh.doan@fda.hhs.gov,
or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-
0572 in the Washington DC area), code 3014512530. Please call the
Information Line for up-to-date information on this meeting.
SUPPLEMENTARY INFORMATION: In the Federal Register of October 26, 2009,
FDA announced that a meeting of the Anti-Infective Drugs Advisory
Committee would be held on December 9, 2009. On page 55057, in the
second column, the Location portion of the document is changed to read
as follows:
Location: Hilton Washington DC North/Gaithersburg, The Ballrooms,
620 Perry Pkwy., Gaithersburg, MD. The hotel telephone number is 301-
977-8900.
[[Page 59571]]
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.
Dated: November 12, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9-27693 Filed 11-17-09; 8:45 am]
BILLING CODE 4160-01-S
